# Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

> **NCT00364351** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 1574 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00364351
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-09
- **Final completion:** 2016-11
- **Target enrollment:** 1574 (ACTUAL)
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364351, "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00364351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*